UA78483C2 - Tumor necrosis factor antagonists for treating and preventing endometriosis - Google Patents

Tumor necrosis factor antagonists for treating and preventing endometriosis Download PDF

Info

Publication number
UA78483C2
UA78483C2 UA2001085895A UA2001085895A UA78483C2 UA 78483 C2 UA78483 C2 UA 78483C2 UA 2001085895 A UA2001085895 A UA 2001085895A UA 2001085895 A UA2001085895 A UA 2001085895A UA 78483 C2 UA78483 C2 UA 78483C2
Authority
UA
Ukraine
Prior art keywords
tme
antagonist
endometriosis
receptor
application according
Prior art date
Application number
UA2001085895A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8237393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA78483(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of UA78483C2 publication Critical patent/UA78483C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UA2001085895A 1999-01-22 2000-01-19 Tumor necrosis factor antagonists for treating and preventing endometriosis UA78483C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99101194A EP1022027A1 (en) 1999-01-22 1999-01-22 Tumor necrosis factor antagonists and their use in endometriosis
PCT/IB2000/000052 WO2000043031A1 (en) 1999-01-22 2000-01-19 Tumor necrosis factor antagonists and their use in endometriosis

Publications (1)

Publication Number Publication Date
UA78483C2 true UA78483C2 (en) 2007-04-10

Family

ID=8237393

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2001085895A UA78483C2 (en) 1999-01-22 2000-01-19 Tumor necrosis factor antagonists for treating and preventing endometriosis

Country Status (30)

Country Link
US (2) US6663865B1 (cs)
EP (2) EP1022027A1 (cs)
JP (1) JP4601176B2 (cs)
KR (2) KR20060128056A (cs)
CN (2) CN100594932C (cs)
AR (1) AR022251A1 (cs)
AT (1) ATE242002T1 (cs)
AU (1) AU771964B2 (cs)
BG (1) BG65556B1 (cs)
BR (1) BR0008182A (cs)
CA (1) CA2356737C (cs)
CZ (1) CZ302866B6 (cs)
DE (1) DE60003152T2 (cs)
DK (1) DK1143997T3 (cs)
EA (1) EA003927B1 (cs)
EE (1) EE05543B1 (cs)
ES (1) ES2200808T3 (cs)
HK (1) HK1043059B (cs)
HU (1) HU226149B1 (cs)
IL (2) IL144413A0 (cs)
NO (1) NO328814B1 (cs)
NZ (1) NZ512585A (cs)
PL (1) PL204713B1 (cs)
PT (1) PT1143997E (cs)
SI (1) SI1143997T1 (cs)
SK (1) SK287313B6 (cs)
TR (1) TR200102107T2 (cs)
UA (1) UA78483C2 (cs)
WO (1) WO2000043031A1 (cs)
ZA (1) ZA200105263B (cs)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU229164B1 (en) * 2001-01-29 2013-09-30 Serono Sa Coinsins Lab Use of il-18 inhibitors for the treatment and/or prevention of heart disease
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1709965A3 (en) 2001-07-11 2006-12-27 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediate diseases
US7082134B1 (en) * 2002-01-18 2006-07-25 Juniper Networks, Inc. Redirect checking in a network device
US20070298041A1 (en) * 2002-06-28 2007-12-27 Tomlinson Ian M Ligands That Enhance Endogenous Compounds
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
DE60325275D1 (de) * 2003-02-07 2009-01-22 Austria Wirtschaftsservice Gmbh Verwendung des menschlichen choriongonadotropins in der behandlung von endometriose-symptomen
US7749999B2 (en) 2003-09-11 2010-07-06 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof
GB0327112D0 (en) 2003-11-21 2003-12-24 Clincial Designs Ltd Dispenser and reservoir
GB0408449D0 (en) 2004-04-15 2004-05-19 Banerjee Subhasis Diagnostic and therapeutic applications of soluble lhcge protein
AU2005249504A1 (en) * 2004-05-28 2005-12-15 Laboratoires Serono Sa Use of IL-17 in the treatment of fertility-related disorders
US20060045902A1 (en) * 2004-09-01 2006-03-02 Serbousek Jon C Polymeric wrap for in vivo delivery of osteoinductive formulations
CN101282646B (zh) * 2005-07-12 2013-03-27 Dmi生物科学公司 治疗疾病的方法和产品
WO2008149147A2 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
ES2523769T3 (es) 2009-06-22 2014-12-01 Ampio Pharmaceuticals, Inc. Procedimiento de tratamiento de enfermedades
SG177302A1 (en) * 2009-06-22 2012-02-28 Dmi Acquisition Corp Methods and products for treatment of diseases
EP2934546A4 (en) 2012-12-19 2016-06-22 Ampio Pharmaceuticals Inc METHOD OF DISEASE TREATMENT
EP3265107B1 (en) 2015-03-02 2024-10-02 180 Therapeutics LP Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037805A (en) * 1989-03-20 1991-08-06 The Salk Institute For Biological Studies Methods of contraception
EP1097945B1 (en) * 1991-03-18 2007-07-04 New York University Monoclonal and chimeric antibody specific for human tumor necrosis factor
US20040120952A1 (en) * 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
KR100232688B1 (ko) * 1992-09-15 1999-12-01 스코트 쥐. 홀퀴스트 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물
US5389657A (en) * 1993-02-01 1995-02-14 Free Radical Sciences Corporation Method for treating infertility
IL111125A0 (en) * 1994-05-11 1994-12-29 Yeda Res & Dev Soluble oligomeric tnf/ngf super family ligand receptors and their use
US5747532A (en) * 1995-11-21 1998-05-05 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5710247A (en) * 1996-03-19 1998-01-20 Abbott Laboratories Process and intermediates for the synthesis of LHRH antagonists
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
ES2326347T3 (es) * 1996-11-27 2009-10-07 Immunex Corporation Metodo para regular la produccion de oxido nitrico.
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors

Also Published As

Publication number Publication date
HK1043059B (zh) 2005-11-18
KR20060128056A (ko) 2006-12-13
NZ512585A (en) 2003-08-29
ZA200105263B (en) 2002-06-26
CA2356737A1 (en) 2000-07-27
KR20010101397A (ko) 2001-11-14
CN1337883A (zh) 2002-02-27
EE200100378A (et) 2002-10-15
AU1997300A (en) 2000-08-07
KR100685106B1 (ko) 2007-02-22
PL350002A1 (en) 2002-10-21
DE60003152T2 (de) 2004-03-25
CN1698894A (zh) 2005-11-23
SK10292001A3 (sk) 2001-12-03
DE60003152D1 (de) 2003-07-10
EA003927B1 (ru) 2003-10-30
NO20013577D0 (no) 2001-07-19
JP4601176B2 (ja) 2010-12-22
HUP0105103A2 (hu) 2002-04-29
BG65556B1 (bg) 2008-12-30
CZ20012656A3 (cs) 2002-02-13
SK287313B6 (sk) 2010-06-07
BR0008182A (pt) 2001-11-06
IL144413A (en) 2009-05-04
HK1043059A1 (en) 2002-09-06
CN1212152C (zh) 2005-07-27
CN100594932C (zh) 2010-03-24
EP1143997B1 (en) 2003-06-04
SI1143997T1 (en) 2003-12-31
TR200102107T2 (tr) 2001-12-21
EP1143997A1 (en) 2001-10-17
JP2002535284A (ja) 2002-10-22
EP1022027A1 (en) 2000-07-26
HUP0105103A3 (en) 2004-08-30
US6663865B1 (en) 2003-12-16
US20040057954A1 (en) 2004-03-25
ES2200808T3 (es) 2004-03-16
EA200100799A1 (ru) 2001-12-24
WO2000043031A1 (en) 2000-07-27
AR022251A1 (es) 2002-09-04
NO20013577L (no) 2001-08-29
NO328814B1 (no) 2010-05-18
PL204713B1 (pl) 2010-02-26
DK1143997T3 (da) 2003-09-15
IL144413A0 (en) 2002-05-23
HU226149B1 (en) 2008-05-28
EE05543B1 (et) 2012-06-15
AU771964B2 (en) 2004-04-08
CZ302866B6 (cs) 2011-12-21
CA2356737C (en) 2010-03-23
PT1143997E (pt) 2003-10-31
ATE242002T1 (de) 2003-06-15
HK1082690A1 (zh) 2006-06-16
BG105691A (en) 2002-02-28

Similar Documents

Publication Publication Date Title
UA78483C2 (en) Tumor necrosis factor antagonists for treating and preventing endometriosis
Eisermann et al. Tumor necrosis factor in peritoneal fluid of women undergoing laparoscopic surgery
Arck et al. Stress-induced murine abortion associated with substance P-dependent alteration in cytokines in maternal uterine decidua
Rennert et al. Selective disruption of lymphotoxin ligands reveals a novel set of mucosal lymph nodes and unique effects on lymph node cellular organization.
Acién et al. Use of intraperitoneal interferon α-2b therapy after conservative surgery for endometriosis and postoperative medical treatment with depot gonadotropin-releasing hormone analog: a randomized clinical trial
Eisenberg et al. Is there an association between autoimmunity and endometriosis?
Gordon et al. Oestradiol applied locally to ripen the unfavourable cervix
Velasco et al. Intraperitoneal recombinant interleukin-2 activates leukocytes in rat endometriosis
HK1082690B (en) Tumor necrosis factor antagonists and their use in endometriosis
Ashish et al. Inflammatory cytokine profile of VEGF and IL-6 from the endometrium of women with and without endometriosis
Young et al. Immunologic aspects of Endometriosis
MXPA01006897A (en) Tumor necrosis factor antagonists and their use in endometriosis
Engemise Effects of the levonorgestrel-releasing intrauterine system and a gonadotrophin releasing hormone agonist in the symptomatic treatment of minimal to moderate endometriosis
Frazier-Jessen The effect of estrogen in a murine model of peritoneal adhesion formation
Cromer et al. Colonic insult impairs lymph flow and cell burden, alters local lymphatic environment and leads to sustained inflammation in the rat ileum